ARCHIVES
VOL. 9, ISSUE 2 (2024)
Diroximel fumarate: An overview
Authors
Mohammad Atika Afreen Shafi, Gangu Sreelatha, K Ratna Jyothi, Tadikonda Rama Rao
Abstract
Diroximel fumarate, sold under the brand name Vumerity, is a medication
used for the treatment of relapsing forms of multiple sclerosis (MS). It acts
as an immunosuppressant and anti-inflammatory drug. Diroximel fumarate is
hypothesized to regulate cell signalling pathways, causing beneficial immune
and neuroprotective effects. It is prescribed for the treatment of relapsing
forms of multiple sclerosis to include clinically isolated syndrome,
relapsing-remitting disease and active secondary progressive disease in adults.
Its most common adverse effects are flushing and gastrointestinal problems. The
drug is available as a white delayed-release capsule that is resistant to
gastric acid and only dissolves in the intestine. Under the European Union's
label, the drug is contraindicated in people with progressive multifocal
leukoencephalopathy (PML), a disease of the brain caused by a virus. In the US,
combination with the closely related drug dimethyl fumarate is contraindicated.
Pages:4-7
How to cite this article:
Mohammad Atika Afreen Shafi, Gangu Sreelatha, K Ratna Jyothi, Tadikonda Rama Rao "Diroximel fumarate: An overview". International Journal of Research in Pharmacy and
Pharmaceutical Sciences, Vol 9, Issue 2, 2024, Pages 4-7
Download Author Certificate
Please enter the email address corresponding to this article submission to download your certificate.